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Prosthesis–patient mismatch is present when the effective orifice area of the inserted
prosthetic valve is less than that of a normal human valve. This is a frequent problem in
patients undergoing aortic valve replacement, and its main hemodynamic consequence is
the generation of high transvalvular gradients through normally functioning prosthetic
valves. The purposes of this report are to present an update on the concept of aortic
prosthesis–patient mismatch and to review the present knowledge with regard to its
impact on hemodynamic status, functional capacity, morbidity and mortality. Also, we
propose a simple approach for the prevention and clinical management of this phenom-
enon because it can be largely avoided if certain simple factors are taken into
consideration before the operation. (J Am Coll Cardiol 2000;36:1131– 41) © 2000 by
the American College of Cardiology
The problem of prosthesis–patient mismatch was first
described by Rahimtoola in 1978 as follows: “Mismatch can
be considered to be present when the effective prosthetic
valve area, after insertion into the patient, is less than that of
a normal human valve” (1). With the advent of Doppler
echocardiography has come the observation that normally
functioning valve prostheses can have relatively high post-
operative transvalvular gradients, and that, in most in-
stances, these high gradients are essentially due to a phe-
nomenon akin to prosthesis–patient mismatch (2– 6).
Hence, prosthesis–patient mismatch is a more frequent
problem than originally believed, and it may have a signif-
icant impact on the long-term results of valve surgery. The
purposes of this report are to present an update on the
concept of aortic prosthesis–patient mismatch and to review
the present knowledge with regard to its impact on hemo-
dynamic status, functional capacity, morbidity and mortal-
ity. We also propose a simple approach for the prevention
and clinical management of mismatch because this phe-
nomenon can be largely avoided if certain simple factors are
taken into consideration before the operation.
DEFINITION OF PROSTHESIS–PATIENT MISMATCH
Several Doppler echocardiographic studies have shown that
most prosthetic valves are at least mildly stenotic and that
relatively high transprosthetic gradients can be observed
after the operation, despite normal prosthesis function
(1,7–18). Physiologically, it must be remembered that trans-
valvular gradients are essentially determined by two factors
(see Gorlin equation): the effective orifice area (EOA) of the
valve and transvalvular flow. In turn, transvalvular flow is
related to cardiac output, which at rest is largely determined
by body surface area. Hence, it is no surprise that the
variable that best correlates with postoperative rest and
exercise gradients is the indexed EOA (i.e., EOA divided by
body surface area [BSA]) (2,4,19,20). Prosthesis–patient
mismatch is deemed to occur when the indexed EOA is
reduced (i.e., when the size of the prosthesis orifice is too
small in relation to the patient’s body size). If one wanted to
make a caricature of prosthesis–patient mismatch, the epit-
ome of this phenomenon would be to insert a mouse’s valve
in an elephant’s aorta. Evidently, there would be a very high
gradient, although the valve might be absolutely normal.
Hence, it has been demonstrated that to avoid any signifi-
cant gradient at rest or during exercise, the indexed EOA of
an aortic valve prosthesis should ideally be no less than 0.85
to 0.90 cm2/m2 (2,4,19,20). This observation is consistent
with the generally accepted concept that moderate aortic
stenosis is present in a native valve when its indexed EOA
is ,0.90 cm2/m2 (21,22). Consequently, one of the objec-
tives of aortic valve replacement should logically be to
ensure that the indexed EOA after the operation is above
these levels to avoid residual stenosis. Nonetheless, prosthe-
sis–patient mismatch has been frequently observed, mostly
for two reasons. First, patients with aortic valve disease
frequently exhibit annulus calcification and fibrosis as well as
left ventricular (LV) hypertrophy, and these pathologic
processes can reduce the size of the aortic annulus. As a
result, a prosthesis too small for the patient’s BSA may have
to be inserted. Moreover, before the concept of mismatch
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became more widely recognized, the consequences of insert-
ing a smaller prosthesis were largely ignored, and there was
no particular effort to insert a larger prosthesis except in rare
cases (3). Second, because the prosthesis is inserted within
the aorta and has its own structural support, the EOA of the
prosthesis is necessarily less than that which a normal native
valve would have within the same aorta. Obviously, the
support apparatus of stented bioprostheses or of mechanical
valves creates a relative obstruction to flow, and it has been
shown that the EOA available for blood flow represents
only 40% to 70% of the total area occupied by the valve
(23–26). Stentless bioprostheses were in part developed to
alleviate this problem, and they generally provide a larger
valve EOA in relation to the patient’s BSA, as compared
with stented bioprostheses (20,27–43). Nonetheless, the
EOA of stentless valves remains somewhat smaller than that
of the corresponding native valve, because they are usually
implanted using techniques requiring insertion of the pros-
thesis within the patient’s aorta (a cylinder within a cylin-
der).
Prosthesis–patient mismatch has been recognized by the
American Society of Thoracic Surgeons and has been
identified as a nonstructural dysfunction (44,45). Indeed,
mismatch is a functional hemodynamic abnormality, rather
than being due to an intrinsic defect of the prosthesis.
Previous studies have demonstrated that mismatch is not
necessarily a rare phenomenon. Hence, using a relatively
conservative definition (i.e., indexed EOA #0.85 cm2/m2),
it was observed in up to 52% of patients with a stented aortic
bioprosthesis (5,6,46).
DETERMINANTS OF MISMATCH
Mismatch has been shown to be more likely to occur in
patients with the following characteristics: larger BSA, older
age, smaller prosthesis size and valvular stenosis as the
predominant lesion before the operation (1,4–6,47). Larger
patients are probably predisposed to mismatch because they
have high cardiac output requirements, and the pathologic
process possibly produced a greater narrowing of their
valvular annulus in relation to their body size, as compared
with smaller patients. Not surprisingly, the incidence of
mismatch also increases with diminishing prosthesis size,
and it is widely recognized that patients with a valve size
#21 mm tend to have much higher gradients (9,14,48–50).
Nonetheless, it must be emphasized that severe mismatch
can also occur in patients receiving a prosthesis size
.21 mm (5,6) and that, ultimately, it is always the relation
between prosthesis size and body size, rather than each
factor taken separately, that determines the final hemody-
namic outcome. Thus, patients who received a smaller
prosthesis probably had a smaller aortic annulus with regard
to their body size. The fact that mismatch occurs more
frequently in patients with stenotic native valves and in older
patients is also consistent with this concept because patients
with stenotic native valves generally have smaller valvular
annuli than those with regurgitant valves (51) and calcific
aortic stenosis is by far the most prevalent lesion in older
patients undergoing aortic valve replacement.
HEMODYNAMIC IMPACT OF MISMATCH
The main consequence of prosthesis–patient mismatch is to
generate high transvalvular gradients through normally
functioning prosthetic valves. The transvalvular gradient is
important to consider because an increased gradient will
evidently result in increased LV work, thus jeopardizing the
regression of LV hypertrophy. An expression of the poten-
tial severity of mismatch is given by the relation showing
that the transvalvular gradient increases exponentially with a
decrease in indexed EOA and that a small decrease in EOA
might result in a relatively large increase in gradient (Fig. 1)
(2,4,20). Accordingly, in a recent study (6), the average
mean gradient of patients with mismatch, as defined by an
indexed EOA #0.85 cm2/m2, was found to be 22 6
8 mm Hg, compared with 15 6 6 mm Hg in patients
without mismatch (Fig. 2A). In patients with an indexed
EOA #0.65 cm2/m2, it was 33 6 2 mm Hg. Moreover,
long-term follow-up showed a deterioration of hemody-
namic measures only in patients with mismatch. Hence,
cardiac index, which was similar in patients with and
without mismatch up to three years after the operation,
decreased significantly thereafter only in patients with
mismatch (20.54 6 0.32 vs. 20.17 6 0.49 liter/min per
m2; p 5 0.04) (Fig. 2B). Although the deterioration in valve
Abbreviations and Acronyms
BSA 5 body surface area
EOA 5 effective orifice area
LV 5 left ventricular
Figure 1. Relations between mean transvalvular pressure gradients and
indexed effective orifice areas for aortic bioprostheses studied in vitro in a
physiologic pulse duplicator system, assuming a normal cardiac index of 3.0
liter/min per m2 at rest and 10% to 50% increases in stroke volume, as may
occur during maximal upright exercise. (Reproduced with permission from
Dumesnil and Yoganathan [4].)
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EOA was similar in both groups, the mean gradient
increased significantly (6 6 6 mm Hg vs. 1 6 1 mm Hg;
p 5 0.0008) only in patients with mismatch during
follow-up (Fig. 2A). Indeed, given the same absolute
decrease in valve EOA, the gradient increases much more in
patients with mismatch, given the curvilinear relation be-
tween gradients and indexed EOAs (Fig. 1). Not surpris-
ingly, the greatest deteriorations in cardiac index and
gradients were seen in the patients with the most severe
mismatch (i.e., with an indexed EOA #0.65 cm2/m2).
Figure 3A was obtained using data from our laboratory; it
shows the relation between transvalvular gradient and in-
dexed EOA 18 6 8 months after aortic valve replacement in
396 patients with either a stented bioprosthesis, a stentless
bioprosthesis, an aortic homograft or a pulmonary autograft.
As can be seen, these patients fall on different sections of the
same exponential curve. The majority of patients with a
stented bioprosthesis have an indexed EOA #0.85 cm2/m2
and are therefore on the steep portion of the curve, where
gradients are relatively high. In contrast, most patients with
a stentless bioprosthesis and almost all patients with an
aortic homograft or a pulmonary autograft have a larger
indexed EOA and are therefore on the flat portion of the
curve, where gradients are relatively low.
Recent studies from this laboratory also show the mean
gradient, as well as the increase in mean gradient during
maximal exercise, can also be directly related to the indexed
EOA at rest (19,20). Indeed, in patients with an aortic
bioprosthesis, we found a strong inverse relation between
the mean gradient during maximal exercise and the indexed
EOA at rest (Fig. 3B). Hence, in patients with mismatch,
defined as an indexed EOA #0.85 cm2/m2, the average
mean gradient during exercise was 30 6 10 mm Hg, which
Figure 2. Postoperative mean transvalvular gradient (A) and cardiac index
(B) as a function of the interval since prosthesis implantation (years) in
patients with an indexed effective orifice area, at implantation, of #0.65
cm2/m2 (closed triangle pointing down, n 5 5), 0.66 to 0.85 cm2/m2
(closed triangle pointing up, n 5 29), 0.86 to 1.05 cm2/m2 (open triangle
pointing up, n 5 29) and .1.05 cm2/m2 (open triangle pointing down,
n 5 9). *Significant difference between patients with an indexed valve area
#0.85 or .0.85 cm2/m2. Data are expressed as the mean value 6 SEM.
(Reproduced with permission from Pibarot et al. [6].)
Figure 3. Correlation between mean transvalvular gradient and indexed
effective orifice area in patients with a stented bioprosthesis (solid circles,
n 5 51), a stentless bioprosthesis (open circles, n 5 194), an aortic
homograft (open triangles, n 5 55) or a pulmonary autograft (open boxes,
n 5 96). Panels A and B show this relation for mean gradient measured at
rest in all patients and during maximal exercise in a subgroup of 48 patients,
respectively. Several points are overlapped.
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is close to that observed in patients with mild to moderate
aortic stenosis (37 6 17 mm Hg) (52), whereas in patients
without mismatch, the average mean gradient was 10 6
5 mm Hg. These exercise studies also demonstrated that the
EOA of a bioprosthesis has the potential to increase during
exercise and that, as a consequence, the observed increase in
gradient is substantially less (;25%) than what would have
been observed if the EOA had remained constant during
exercise (20). Nonetheless, it should be submitted that
bioprostheses that have calcified over time or mechanical
prostheses are probably less compliant and thus could have
a greater increase in gradient during exercise. Indeed, recent
studies performed in patients with mechanical valves sug-
gest that the EOA of these patients does not increase during
exercise, resulting in a relatively greater increase in gradient
(41,53,54). Further studies are necessary to resolve these
issues, but these results underline the necessity of evaluating
the performance of the prosthesis not only at rest, but also
during exercise.
Also, the impact of mismatch may be overestimated in
patients with a smaller aortic root owing to the pressure
recovery phenomenon. Indeed, recent studies have demon-
strated that there is substantially more pressure recovery
occurring downstream to native or prosthetic aortic valves in
patients with a small aorta as compared with patients with
a large aorta (55–58). Hence, given a similar indexed EOA,
patients with a smaller aorta will have less energy loss and
thus less burden on their LV than those with a larger aorta.
We have recently proposed a new index of aortic stenosis
severity, taking into account the influence of pressure
recovery, but it remains to be validated in larger prospective
series of patients with native stenosis as well as with
prostheses (58).
IMPACT ON LV HYPERTROPHY
A major consequence of high residual pressure gradients is
the hindrance or delay of the regression of LV hypertrophy
after the operation (59–61). Indeed, the extent of muscle
mass regression has been shown to be highly dependent on
the type and size of prosthesis used for valve replacement, as
well as on their hemodynamic performance (61–63). Hence,
Barner et al. (64) demonstrated that regression of LV
hypertrophy after aortic valve replacement is better in
patients with a prosthesis size .21 mm (221%) than in
patients with a prosthesis size #21 mm (28%), and
Nishimura et al. (60) found that the mean wall thickness of
the LV was directly related to the pressure gradient across
the aortic prosthetic valve. Other studies also demonstrate
that aortic valve replacement with a stentless bioprosthesis is
associated with a greater decrease in transvalvular gradient
and LV wall stress, as well as with more complete regression
of LV hypertrophy, compared with stented valves
(20,61,65). In a recent study of 1,103 patients with a porcine
bioprosthesis, Del Rizzo et al. (66) found a strong relation
between the indexed EOA and the extent of LV mass
regression. At three years after the operation, the LV mass
index had decreased by 23%, on average, in patients whose
indexed EOA was .0.8 cm2/m2, as compared with 4.5%
(p 5 0.0001) in patients with an indexed EOA ,0.8
cm2/m2. In contrast, no difference was noted between the
patients with an indexed EOA between 0.8 and 1.0 cm2/m2
and those with an indexed EOA .1.0 cm2/m2 (224% vs.
222%). These results are consistent with the relations
shown in Figure 3, where the gradients are more important
only when the indexed EOA is ,0.8 to 0.9 cm2/m2.
Thereafter, the curve is relatively flat and the transvalvular
gradients are low, regardless of the level of indexed valve
EOA, thus resulting in an optimal regression of LV
hypertrophy.
In this context, it should be emphasized that LV hyper-
trophy has long been recognized as an important risk factor
and predictor of survival as well as a major determinant of
systolic and diastolic function and exercise capacity (67–73).
However, a caveat should be made that most studies
showing long-term detrimental effects of LV hypertrophy
were conducted in patients with hypertensive heart disease.
It remains to be determined whether similar consequences
are to be expected with respect to the hypertrophy due to
valvular disease. Indeed, the hypertrophy associated with
hypertension shows an important proportion of interstitial
fibrosis in addition to muscle hypertrophy, and it has a
neurohormonal component (73). The hypertrophy due to
valvular disease could be different and more directly related
to an increased hemodynamic burden, in which case it could
be more physiologic, show less fibrosis and thus not have the
same negative impact on long-term prognosis. Indeed,
numerous studies have shown that the physiologic hyper-
trophy due to exercise is directly related to the increased
burden related to the intensity of training and does not carry
any long-term negative effects (74–76).
CLINICAL IMPACT OF MISMATCH
Impact on physical capacity. The postoperative improve-
ment of the patient’s physical capacity is an important
objective of valve replacement because it directly influences
the patient’s symptomatic status, quality of life and rate of
re-employment (77–80). Poor physical capacity is also
associated with a higher rate of late mortality after valve
replacement (81,82). Fernandez et al. (83) reported that the
indexed EOA did not influence the New York Heart
Association functional class in patients with a St. Jude
bileaflet valve, whereas we (6) have found that the indexed
EOA is an independent predictor of functional class in
patients with a Medtronic Intact bioprosthetic valve. The
discrepancy between the results of these two studies might
be due to the fact that the indexed EOAs (range 0.74 to
2.86 cm2/m2) in the former study were larger than those in
the latter study (range 0.57 to 1.59 cm2/m2), and few
patients in the study by Fernandez et al. (83) had an indexed
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EOA ,0.85 cm2/m2, which is the generally accepted
criteria for prosthesis–patient mismatch.
Conflicting results are also observed when exercise capac-
ity is measured directly. On the one hand, there are some
studies (10,64,84) demonstrating that prosthesis size is an
independent predictor of exercise tolerance after aortic valve
replacement. Moreover, de Carlo et al. (85) reported that
among patients with a 21-mm St. Jude mechanical valve,
those with a BSA $1.70 m2 had significantly lower exercise
tolerance than those with a BSA ,1.70 m2. Furthermore,
the indexed valve EOA was an independent predictor of
exercise tolerance variables. On the other hand, recent
studies of patients with bioprosthetic valves show that
maximal exercise capacity, as estimated by maximal work-
load, peak oxygen consumption or anaerobic threshold, is
similar between patients with an indexed EOA #0.85 and
.0.85 cm2/m2 (19,20). As previously mentioned, the results
of this study suggest that these bioprosthetic valves were
compliant and these patients had the capacity to substan-
tially increase their EOA during exercise, whereas this may
not be the case with mechanical valves; as a result, the
gradients measured during exercise are less than expected
and probably not high enough to have a significant impact
on maximal exercise capacity. Because patients with mis-
match often have a small aortic root, it is also possible that
some of these patients had substantial pressure recovery
downstream to their prosthesis and thus better functional
status than one would expect on the basis of the indexed
EOAs and gradients measured by Doppler echocardiogra-
phy.
Impact on postoperative morbidity. Two studies (6,83)
have failed to demonstrate any association between the valve
EOA indexed for BSA and the incidence of valve-related
complications, such as thromboembolism, hemorrhage,
structural valve deterioration and re-operation. However, a
transversal study (5) in 61 patients with an aortic biopros-
thesis showed that the occurrence of adverse clinical events
not related to the valve was significantly higher in patients
with an indexed EOA #0.85 cm2/m2 (50% vs. 21%; p 5
0.02). A longitudinal study (6) in patients with a stented
bioprosthesis also suggested that mismatch could predispose
them to the long-term development of heart failure,
whether or not it is related to the prosthetic valve, but this
was not confirmed as an independent predictor by multi-
variate analysis. It is therefore difficult to ascertain whether
the difference between the two groups was related to the
presence of mismatch or to other undetermined factors. Of
the 392 patients followed for up to seven years, only two
(0.5%) needed re-operation because they had severe mis-
match and became symptomatic. Obviously, further long-
term studies appear warranted. It is possible that the
follow-up periods in these previous studies were not long
enough to detect more significant differences. Nonetheless,
medium-term prognosis with respect to postoperative mor-
bidity appears relatively good. Future longitudinal studies
may also be more difficult to perform or may even become
obsolete, because awareness with regard to mismatch is
increasing, and, as will be shown, this mismatch can largely
be avoided.
Impact of mismatch on postoperative mortality. Several
previous studies have demonstrated that mortality was
higher in patients receiving a small (#21 mm) aortic
prosthesis (86–88). For instance, Abdelnoor et al. (86)
found that the five-year survival rate relative to a normal
population was significantly lower in patients receiving a
small aortic prosthesis (63%) than in the total cohort of
patients (87%). Furthermore, Kratz et al. (89) reported that
mortality 10 years after the operation was higher when a
small (19 or 21 mm) St. Jude aortic valve prosthesis was
implanted in a patient with a BSA .1.9 m2. In this context,
it should be remembered that a small valve size is more
likely to be associated with significant prosthesis–patient
mismatch (5), and it is highly possible that the patients
reported in these studies were more extreme cases of
mismatch, but this is difficult to ascertain given that the
aforementioned studies often do not report values for
indexed EOAs. Also, a smaller valve size may actually be an
indicator of additional risk factors, such as a senescent aortic
stenosis, a small calcified aortic root, marked LV hypertro-
phy and a smaller BSA (87). Finally, the implantation of a
prosthesis in a small calcified aortic root can be technically
more difficult and often requires a longer aortic cross-clamp
time, which is a major risk factor in these patients (86,90).
From these findings, it becomes evident that further longi-
tudinal studies are necessary to determine whether the
higher mortality associated with smaller valve sizes is due to
prosthesis–patient mismatch or to the other aforementioned
factors. To clarify this, it is important to report the results
for the indexed EOA and to include them in the risk factor
analysis.
Two previous studies in a relatively small number of
patients failed to demonstrate a negative impact of mis-
match (i.e., of the indexed valve EOA at operation) on
short- and medium-term (up to eight years) mortality
(6,83). However, in a recent study of 2,516 patients who
underwent aortic valve replacement with a stented biopros-
thetic valve, Rao et al. (91) showed that patient age (relative
risk 1.07, 95% confidence interval 1.04 to 1.09) and indexed
valve EOA (relative risk 1.46, 95% confidence interval
0.95 to 2.24), but not prosthesis size, were independent
predictors of postoperative valve-related mortality. Mis-
match had a significant impact on survival when the indexed
EOA of the prosthetic valve at the time of the operation was
,0.75 cm2/m2 (75 6 5% vs. 84 6 2%; p 5 0.004) at 12
years. This is somewhat in contrast with studies of native
aortic valves showing that aortic stenosis is generally asso-
ciated with higher morbidity and mortality rates when the
indexed EOA is ,0.60 cm2/m2 (21,22). This apparent
discrepancy could be due to the fact that Rao et al. used in
vitro EOA values to calculate their indexed EOAs and that,
although there is a good correlation between the two, in
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vitro EOAs tend to overestimate in vivo EOAs by 10% to
15% (2,14,92,93).
MANAGEMENT AND PREVENTION OF MISMATCH
Clinical management of mismatch. The finding of a high
transvalvular pressure gradient in a patient with a prosthetic
valve is often a difficult diagnostic challenge. High
transprosthetic pressure gradients may be present after
aortic valve replacement, either because of intrinsic stenosis,
a state of high cardiac output or prosthesis–patient mis-
match. The most logical approach for assessing intrinsic
prosthesis performance is to compare the EOA measured by
Doppler echocardiography to the reference values measured
either in vitro or in vivo for the same model and size of
prosthesis. A value substantially lower than the reference
values would certainly suggest an intrinsic stenotic process
(e.g., tissue ingrowth, thrombus, calcification), and even
more so if there had been a progressive decline of the EOA
over time. In such cases, replacement of the prosthetic valve
should be considered, because intrinsic stenosis processes
are usually progressive. If the finding of a high transvalvular
gradient is mainly due to prosthesis–patient mismatch, as
indicated by an EOA consistent with normal reference
values but an indexed EOA #0.85 cm2/m2, there are no
precise guidelines at present; however, given that these
patients have a relatively good medium-term prognosis but
may show hemodynamic deterioration and higher mortality
in the long term (6,91), it would seem logical to follow them
more closely. If, on the other hand, the patient develops the
usual symptoms associated with aortic stenosis (i.e., angina,
dyspnea or syncope) and has an indexed EOA compatible
with severe stenosis (i.e., #0.60 cm2/m2), he or she should
certainly be considered for re-operation, as is the case for
native valves (22). In patients with mismatch undergoing
re-operation, it would be very important to insert a pros-
thesis that will provide a larger indexed EOA, resulting in
better hemodynamic performance. For this purpose, the
surgeon could insert a prosthesis with a larger EOA either
because it is of a larger size or a different type. If aortic root
enlargement is contemplated, its risks must be weighed
against the anticipated benefits.
Prevention of mismatch. To avoid prosthesis–patient mis-
match, we would suggest a simple three-step algorithm that
can easily be performed in the operating room (Table 1):
Step 1—Calculate the patient’s BSA from weight and
height using the equation or the chart proposed by Dubois
(94). Step 2—Refer to Table 1, which shows the determi-
nation of the minimal valve EOA required to ensure an
indexed EOA .0.85, .0.80 or .0.75 cm2/m2, given the
patient’s BSA as calculated in step 1; the choice between
0.85, 0.80 and 0.75 cm2/m2 is based on what is deemed to
be the minimal requirement for a given patient, with the
knowledge that 0.85 cm2/m2 or higher is the optimal value
for better hemodynamics. Step 3—Select the type and size
of prosthesis that has reference values for EOA
(2,3,13,14,26,39,93,95–102) greater or equal to the minimal
EOA value obtained in step 2. Such values are provided in
Table 2.
When examining the values in Table 2, the following
points are important to remember:
1) Ideally, the reference values should be as representative
as possible of the in vivo performance of the prostheses,
and for this reason, we are giving the available in vivo
values from the published data. Manufacturers also have
in vitro values derived from premarketing studies; these
values usually overestimate in vivo values by 10% to 15%,
but otherwise correlate well with in vivo values
(2,14,92,93). One notable exception is stentless valves,
whose in vitro values for EOA grossly overestimate in
vivo values and cannot be relied on (39). Our suggestion
would therefore be that both in vitro and in vivo values
for EOA be readily provided by the manufacturers, as
they become available. Except in the case of stentless
valves, in vitro values could temporarily be used as a
reference until the in vivo values can be provided. Also,
Table 1. Three Easy Steps to Avoid Prosthesis–Patient Mismatch
Step I: Calculate the patient’s body surface (BSA) area using the
formula:
BSA 5 ([Weightkg]
0.425 3 [heightcm]
0.725) 3 0.007184
Step II: Determine the minimal requirement for prosthetic valve
effective orifice area (EOA) to avoid prosthesis–patient mismatch.
Patient BSA
(m2)
Minimal Valve
EOA (cm2) for
Indexed EOA
>0.85 cm2/m2
(Ideal)
Minimal Valve
EOA (cm2) for
Indexed EOA
>0.80 cm2/m2
Minimal Valve
EOA (cm2) for
Indexed EOA
>0.75 cm2/m2
1.30 1.11 1.04 0.98
1.35 1.15 1.08 1.01
1.40 1.20 1.12 1.05
1.45 1.23 1.16 1.09
1.50 1.28 1.20 1.13
1.55 1.32 1.24 1.16
1.60 1.36 1.28 1.20
1.65 1.40 1.32 1.24
1.70 1.45 1.36 1.28
1.75 1.49 1.40 1.31
1.80 1.53 1.44 1.35
1.85 1.57 1.48 1.39
1.90 1.62 1.52 1.43
1.95 1.66 1.56 1.46
2.00 1.70 1.60 1.50
2.05 1.74 1.64 1.54
2.10 1.79 1.68 1.58
2.15 1.83 1.72 1.61
2.20 1.87 1.76 1.65
2.25 1.91 1.80 1.69
2.30 1.96 1.84 1.73
2.35 2.00 1.88 1.76
2.40 2.04 1.92 1.80
2.45 2.08 1.96 1.84
2.50 2.13 2.00 1.88
Step III: Choose a prosthesis using reference values for EOA of
different types and sizes of prostheses (see Table 2).
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the in vivo values should ideally be taken at one year after
the operation, because hemodynamic data may change
during the first year (39,40,103,104). Finally, it should
be remembered that in vivo EOA values for bileaflet
valves may artifactually be underestimated when evalu-
ated by Doppler echocardiography owing to localized
high velocity jets (105–108), and hence, in this case, a
value for EOA lower than the reference value does not
necessarily indicate prosthesis dysfunction.
2) For similar prosthesis size, the EOA can vary consider-
ably depending on the type of prosthesis. Hence, in
general, mechanical prostheses tend to have a larger
EOA than bioprostheses, except for stentless biopros-
theses, whose performance may be equivalent or better.
Evidently, within the same category of prosthesis, per-
formance can vary considerably from one manufacturer
to the other.
3) Unfortunately, there are often important discrepancies
between the actual prosthesis ring outer diameter and
the manufacturer’s labeled valve size (109–111). Better
standardization is desirable, but for the time being,
sizing must be performed in the operating room using
the sizer relevant to the prosthesis considered for inser-
tion. The reference values for EOAs should therefore be
readily available in the operating room to determine
whether a particular prosthesis meets the requirements
to avoid prosthesis–patient mismatch. If not, the inser-
tion of a larger prosthesis size or that of a different type
with a better hemodynamic performance should be
considered.
The insertion of a larger prosthesis may require enlargement
of the aortic root (112–114), in which case the increased
operative risk must be weighed against the anticipated benefits.
Other alternatives to avoid mismatch include performing a
supra-annular implantation (49,112,115) or choosing a differ-
ent type of prosthesis. In this context, the advent of stentless
bioprostheses represents a major advance, because these
prostheses generally have a much better hemodynamic
performance than stented bioprostheses both at rest and
during exercise (20,28–32,37–41,43). Indeed, stentless bio-
prostheses provide a larger EOA in relation to the patient’s
BSA, resulting in a larger indexed EOA and a lower
gradient at any given flow level (Fig. 3) (20). The superior
hemodynamic performance of stentless valves is due to the
fact that, size for size, their EOA is generally larger than
that of stented valves. Moreover, for the stentless valves, a
larger prosthesis can be inserted in a smaller annulus
(32,36,39,42). Hence, Walther et al. (42) have recently
shown in a randomized clinical trial that the prosthetic valve
size is larger in the patients receiving a stentless biopros-
thesis (25 6 2 mm) than in those receiving a stented
bioprosthesis (23 6 2 mm), despite a similar size of the
anatomic aortic annulus (24 6 2 mm in both groups). Other
attractive alternatives also include aortic homografts
(116,117) or pulmonary autografts (Ross procedure) (118–
121), which provide an indexed EOA similar to that of the
normal native aortic valve (Fig. 3).
These alternative surgical techniques require a longer
learning period and are frequently associated with longer
aortic cross-clamp times and increased blood loss during the
operation (112,122–124). In analyzing the different options,
Table 2. Normal Effective Orifice Areas for the Most Currently Used Prosthetic Valves
Prosthetic Valve Size (mm) 19 21 23 25 27 29 Reference no.
Stented Bioprosthetic valves
Medtronic Intact 0.85 1.02 6 0.10 1.27 6 0.11 1.40 6 0.20 1.66 6 0.16 2.04 6 0.23 (2)
Medtronic Mosaic — 1.22 6 0.27 1.38 6 0.23 1.65 6 0.39 1.59 6 0.33 1.65 6 0.37 (95)
Hancock II — 1.18 6 0.11 1.33 6 0.16 1.46 6 0.15 1.55 6 0.18 1.60 6 0.15 (3)
Carpentier-Edwards SAV 2650 — 1.16 6 0.14 — — — — (96)
Carpentier-Edwards Pericardial 2900 1.10 1.30 1.50 1.80 1.60 — (97)
Stentless bioprosthetic valves
Medtronic Freestyle 1.15 1.35 6 0.21 1.48 6 0.33 2.00 6 0.39 2.32 6 0.48 — (39)
1.29 6 0.19 1.46 6 0.32 1.79 6 0.33 2.34 6 0.69 2.67 6 0.75 — (98)
St. Jude Medical Toronto SPV — 1.30 1.50 1.70 2.00 2.50 (SJM†)
— 1.49 6 0.45 1.70 6 0.78 2.12 6 0.66 2.70 6 1.03 (99)
Prima Edwards 0.80 1.10 1.50 1.80 2.30 2.80 (100)
Mechanical valves
Medtronic Hall 1.19 6 0.21* 1.34 6 0.15 — — — — (96)
Carbomedics Standard 1.00 6 0.40 1.54 6 0.31 1.63 6 0.30 1.98 6 0.41 2.41 6 0.46 2.63 6 0.38 (93)
1.11 6 0.13 1.52 6 0.22 1.84 6 0.25 2.12 6 0.31 2.65 6 0.21 — (14)
St. Jude Medical Standard — 1.73 6 0.38 2.13 6 0.61 — — — (101)
— 1.76 6 0.47 2.11 6 0.63 — — — (26)
1.04 6 0.19 1.38 6 0.22 1.52 6 0.26 2.08 6 0.41 2.65 6 0.58 3.23 6 0.30 (13)
St. Jude Medical Hemodynamic Plus 1.30 6 0.30 — — — — — (102)
— 2.01 6 0.17 — — — — (101)
— 2.15 6 0.29 — — — — (26)
*The label valve size of this valve is 20 mm. †Data provided by St. Jude Medical.
Effective orifice areas are expressed as the mean value 6SD cm2. The effective orifice areas were measured by Doppler echocardiography using the continuity equation in
patients with normally functioning prostheses. Some data appear conflicting or are based on limited series and may have to be revised as more data become available.
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it is therefore important to consider whether the benefits of
avoiding prosthesis–patient mismatch overcome the draw-
backs of using these techniques. First, mild degrees of
prosthesis–patient mismatch may be acceptable when the
surgical risk is high, whereas severe mismatch may not be
acceptable. Second, the level of physical activity of the
patient is an important variable to consider, because what
would be acceptable for an older sedentary patient would
not necessarily be adequate in a young active patient. In this
context, the relations given in Figure 3 can be useful in
predicting the rest and exercise postoperative gradients from
the projected indexed EOA, which can easily be calculated
in the operating room by dividing the reference value for the
EOA of the prosthesis being implanted (Table 2) by the
patient’s BSA. In making these choices, one must also
realize that knowledge is still evolving and that newer data
on the long-term impact of mismatch on mortality and
morbidity are progressively becoming available. As dis-
cussed, there are presently limitations in determining the
“critical” indexed EOA at which adverse events occur, and
these new data should contribute to the refinement of
strategy for mismatch prevention. Nonetheless, the knowl-
edge of these variables provides the framework for making
more enlightened decisions, because the hemodynamic out-
come is no longer an unknown variable but can be fore-
casted before the operation. In addition, it provides the
impetus for the development of better performing prosthe-
ses.
Conclusions. Patients with evidence of aortic prosthesis–
patient mismatch have less symptomatic improvement and
worse hemodynamic data after aortic valve replacement.
Furthermore, the hemodynamic status progressively deteri-
orates during follow-up, and mismatch has negative impacts
on the regression of LV hypertrophy, as well as on long-
term survival. Nonetheless, aortic prosthesis–patient mis-
match can largely be avoided by calculating, before the
operation, the indexed EOA from reference values for the
EOA of the prosthesis being implanted and the patient’s
BSA, remembering that for optimal valve performance at
rest and exercise, the indexed EOA at rest should ideally be
no less than 0.85 to 0.90 cm2/m2. However, achievement of
such a goal must be evaluated in light of the anticipated risks
and benefits for a given patient.
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